Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific regionExpected to improve profitability through manufacturing cost reductions to advance toward the 2030 VisionCost reductions anticipated to begin contributing during 2027 through to the end of 2028 Tokyo, Japan and Cambridge and London, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Nxera Pharma Japan Co., Ltd. (a wholl ...